ArticleIBRO neuroscience reports2025
Circulating microRNA-219 in stroke: Lack associations with clinical parameters and post-stroke epilepsy risk.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of circulating miR-210 with post-stroke seizures and clinical outcome: A preliminary study.IBRO neuroscience reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke epilepsy (PSE) is a significant complication in stroke survivors, yet early diagnostic biomarkers remain unclear. This study investigated whether circulating microRNA-219 (miR-219) could serve as a reliable biomarker for early detection of PSE. Methods: Serum samples (2 mL) were collected from 40 stroke patients and 20 healthy controls. Circulating miR-219 was measured using real-time PCR. The predictive performance of miR-219 and the PoSERS model for PSE was evaluated using ROC analysis. Demographic and clinical information, including age, gender, stroke subtype, and lesion location, was recorded. Results: Significant differences were observed in stroke subtype (ischemic vs. hemorrhagic) and lesion location (cortical vs. subcortical) between patients with and without PSE (P < 0.05). Triglyceride (TG), HbA1C, and cholesterol levels also differed significantly (P < 0.05). Circulating miR-219 was significantly elevated in stroke patients compared to controls (P < 0.05). However, no significant differences in miR-219 levels were observed between patients with and without PSE. Similar trends were observed when comparing survivors vs. non-survivors, ischemic vs. hemorrhagic stroke, and cortical vs. subcortical lesions. MiR-219 had no predictive value for PSE (AUC=0.49), unlike the PoSERS model (AUC=0.72). Conclusions: Although a significant difference in circulating miR-219 was observed between stroke patients and healthy subjects, it cannot serve as a biomarker to predict the development of PSE. Given the limited sample size, the predictive potential of miR-219 should be confirmed in future studies with larger sample sizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.